• Eltanexor, XPO1, and Colorectal Cancer Prevention

  2026-10-10

  A 2024 bioRxiv preprint reports that XPO1 inhibition with Eltanexor reduces colorectal cancer-related signaling through effects on Wnt/β-catenin activity, COX-2 expression, and FoxO3a nuclear retention. In an Apcmin/+ mouse model, treatment was associated with lower tumor burden and smaller tumors, but the findings remain pre-peer-review and require validation before clinical conclusions can be drawn.

• FLT3–TAZ Signaling and Drug Resistance in BP-CML

  2026-10-09

  Shin et al. reposition FLT3 as a prognostic marker and therapeutic vulnerability in blast phase chronic myeloid leukemia, linking it to a JAK–STAT3–TAZ–TEAD–CD36 signaling axis that supports resistance to BCR::ABL1 tyrosine kinase inhibitors. The study is notable for integrating engineered cell models, patient samples, multi-omics analyses, and xenograft evidence, while also defining important boundaries between preclinical findings and clinical applicability.

• BFH772 VEGFR2 Inhibitor: Product Overview

  2026-10-09

  BFH772 is a supplier-listed small-molecule VEGFR2 inhibitor for conceptual research on VEGFR2 signaling and angiogenesis. No matched paper evidence was supplied, so product claims are not independently validated here.

• Wortmannin in PI3K Signaling Research

  2026-10-08

  A source-grounded overview of Wortmannin as a research tool for studying PI3K signaling, ferroptosis, autophagy, apoptosis, and cancer biology, with emphasis on evidence quality, pharmacological limitations, and the 2026 hepatocellular carcinoma study.

• SARS-CoV-2 PLpro and ER Protein Regulation

  2026-10-08

  Yang and colleagues show that membrane-anchored SARS-CoV-2 papain-like protease can regulate endoplasmic-reticulum proteins through both deubiquitination and proteolytic cleavage. The study distinguishes substrate-specific effects on INSIG-1, SREBP-1, and SREBP-2, expanding the view of PLpro beyond viral polyprotein processing and innate-immune antagonism.

• Shenqi Fuzheng, SRC/PI3K/AKT, and Glioma

  2026-10-07

  This study combines network pharmacology with cell-based and mouse-model evidence to investigate how Shenqi Fuzheng injection may affect glioma proliferation and migration. Its central contribution is the identification of SRC/PI3K/AKT signaling as a candidate mechanistic axis, while the experimental findings support—but do not by themselves prove—a causal, pathway-exclusive explanation.

• MK 0893 and the Extra-Helical GCGR Binding Site

  2026-10-07

  Jazayeri and colleagues reported a 2.5 Å structure showing that MK-0893 binds an unexpected allosteric pocket outside the seven-transmembrane bundle of the glucagon receptor. The study connects this site to restriction of TM6 movement, providing a structural framework for interpreting glucagon receptor antagonist pharmacology and future type 2 diabetes research.

• 1-Myristoylglycerophosphocholine: Evidence and Limits

  2026-10-06

  1-myristoylglycerophosphocholine, also called 14:0 Lyso-PC, is a defined lysophosphatidylcholine species used in lipid signaling research. A 2024 Respiratory Research study linked LysoPC accumulation from injured alveolar type II epithelial cells with fibroblast activation and experimental pulmonary fibrosis, while implicating an HMGCS2–PPARα–CPT1A/CPT2 pathway. However, the study examined LysoPCs as a class rather than establishing that 14:0 Lyso-PC alone drives the reported effects. This overview compares the evidence, identifies conceptual applications in lipid signaling pathway analysis and smooth muscle research, and defines important limits on interpretation.

• CAMLs in Blood: Phenotype and Clinical Utility

  2026-10-06

  Adams and colleagues report a prospective, multi-institutional evaluation of circulating cancer-associated macrophage-like cells, or CAMLs, as phagocytic polyploid giant cancer cells associated with progression and disease spread. The study’s main contribution is to connect a distinctive circulating cell phenotype with metastatic-niche biology while defining the evidence as clinically promising but observational rather than causally or diagnostically conclusive.

• Dantrolene Sodium Salt in Calcium and DNA Repair Research

  2026-10-05

  Dantrolene sodium salt is best supported as a ryanodine receptor antagonist and calcium-signaling research compound. A 2025 CRISPR screen identified drug-associated shifts in DNA double-strand-break repair, but the supplied study summary does not establish dantrolene as a validated NHEJ, MMEJ, or HDR modulator. This overview compares the evidence, outlines conceptual applications, and defines important limitations.

• Gemcitabine in Cholangiocarcinoma Research

  2026-10-05

  This overview examines Gemcitabine as a DNA synthesis–targeting anticancer compound within cholangiocarcinoma research, with emphasis on the 2025 Nature Communications study linking PDHA1 succinylation, α-ketoglutarate, macrophage antigen presentation, and chemotherapy sensitivity. It distinguishes reported preclinical findings from interpretation and outlines evidence limitations without providing experimental procedures.

• BFH772 VEGFR2 Inhibitor: Product Overview

  2026-10-04

  BFH772 is an APExBIO-listed small-molecule VEGFR2 inhibitor intended for conceptual research on VEGFR2-associated angiogenic signaling. No matched paper evidence was provided, so supplier-reported activity, selectivity, and biological claims remain independently unverified here.

• EPZ5676 and the Translational Logic of DOT1L Inhibition

  2026-10-03

  A source-grounded perspective on EPZ5676, DOT1L biology, MLL-rearranged leukemia research, evidence boundaries, and the strategic value of selective epigenetic probes.

• AAL-993: VEGF Receptor Inhibitor Workflows

  2026-10-02

  AAL-993 enables a focused strategy for connecting VEGFR kinase inhibition with endothelial and tumor phenotypes. This workflow combines target-level potency, angiogenesis assays, and carefully bounded comparisons with the SRC/PI3K/AKT findings reported in glioma research.

• Milk-Derived Vesicle Uptake in Intestinal Organoids

  2026-10-01

  This study develops three porcine intestinal stem cell–based models to examine milk-derived extracellular vesicle uptake in physiologically relevant epithelium. Its central findings are that uptake depends on epithelial polarity, differs among organoid formats, and is sensitive to endocytosis inhibition, while colon-derived models show transcriptional responses associated with stemness and differentiation.

8143 records 1/543 page Next 12345 下5页 Last page